ARCHIVES

FDA Oncologic Drugs Advisory Committee: Trials In A Small Indication Tell Big Story About Pitfalls of Delaying Progression

This article is from The Cancer Letter archive.

Vol. 37 No. 15 | April 15, 2011

Download PDF Visit The Full Archive

Related Articles

Phase III Nexavar Trial Fails Primary Endpoint

August 29, 2014

DCPC Board Ponders Screening Recommendations: Should NCI Have Policies? If So, What Will They Be?

September 26, 1986

Mammography’s Best Role Is Screening, Kopans Assert

March 18, 1994

Trials Approved In October

December 28, 2001

Includes April issue of Business & Regulatory Report (8 pages).

May 2, 2003

DCCR Merit Review Finds some Excellent contract Projects, Some Not So Good; Some Are Terminated

February 25, 1977